Richard Lafayette, MD, FACP - Novel Therapies in Focus: Updates in IgA Nephropathy

Visit https://www.peervoice.com/CZH860 to view the entire programme with slides. After completing “Richard Lafayette, MD, FACP - Novel Therapies in Focus: Updates in IgA Nephropathy”, participants will be able to: Distinguish between the clinical trials examining new and emerging therapies in IgA nephropathy (IgAN); Recognize the mechanistic rationale for targeting the drivers of immunopathogenesis in IgAN; and Evaluate clinical evidence and data regarding emerging therapies in patients with IgAN.